Companies › Red de Terapia Celular
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Gastroenterology, Immunology, Metabolic and endocrine; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mesenchymal stem cells (MSC) Bone marrow-derived mesenchymal stem cells for immunomodulation in lupus nephritis | – | Phase 2 | Lupus Nephritis; Chronic Pancreatitis; Diabetes Mellitus, Type 1 | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05925036 | Mesenchymal stem cells (MSC) | Phase 1 | Chronic Pancreatitis | Gastroenterology | Dec 2026 |
| NCT04061746 | Mesenchymal stem cells (MSC) | Phase 1 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | May 2027 |
| NCT03673748 | Mesenchymal stem cells (MSC) | Phase 2 | Lupus Nephritis | Immunology | Dec 2027 |
No annotated target.
–
Biocomposites Estar Medical dba Medical Technologies Restem Xentria Wellizen Australia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.